Imidazoquinoline derivatives (IMDs) and related compounds function as synthetic agonists
of Toll-like receptors 7 and 8 (TLR7/8) and one is FDA approved for topical antiviral and skin …

Toll-like Receptor 4 (TLR4) agonists have had a long journey in the field of cancer
immunotherapy. Nevertheless, despite the remarkable number of the TLR4 ligands that …

Checkpoint inhibitors have demonstrated efficacy in patients with recurrent or metastatic
head and neck squamous cell carcinoma (HNSCC). However, the majority of patients do not …

Imidazoquinolines (IMDs), such as resiquimod (R848), are of great interest as potential
cancer immunotherapies because of their ability to activate Toll-like receptor 7 (TLR7) …

Upon priming with Candida albicans or with the fungal cell wall component β-glucan,
monocytes respond with an increased cytokine production upon restimulation, a …

The innate immune pathway is receiving increasing attention in cancer therapy. This
pathway is ubiquitous across various cell types, not only in innate immune cells but also in …

Toll-like receptors (TLRs) are prototypic pattern recognition receptors (PRRs) best known for
their ability to activate the innate immune system in response to conserved microbial …

Toll-like receptors (TLRs) are pattern recognition receptors, originally discovered to
stimulate innate immune reactions against microbial infection. TLRs also play essential roles …

Disease and enhanced microbial load are considered to be major factors limiting the
performance and overall efficiency of feed use by pigs in Australian piggeries. It is …

Encouraging results are emerging from systems that exploit Toll like receptor (TLR)
signaling, nanotechnology, checkpoint inhibition and molecular imaging for cancer …